5 best ePRO platforms for MedTech and medical device studies in 2026

When your post-market study spans 33 sites and 1,300 participants, an electronic patient-reported outcome (ePRO) platform that buries patients in friction doesn't just hurt retention — it threatens the regulatory submission your device program depends on. Viedoc's ePRO software delivers 98% visit compliance across 7,500+ studies in 75+ countries, with support for 50+ languages, native integration with Viedoc's electronic data capture (EDC) system, and 21 CFR Part 11 compliance built in from day one. This comparison evaluates five leading ePRO platforms for MedTech and medical device studies across patient compliance, EDC integration, language support, regulatory posture, and fit for post-market and observational study designs.

Medical device programs have specific data collection challenges that pharma-centric ePRO tools weren't designed to solve. Your study populations are often older, less technically confident, and running across diverse care settings — from academic centers to outpatient clinics. You need outcome capture that works on any device, with reminders that actually drive completion, and data that flows directly into your EDC without a reconciliation step.

Enterprise ePRO suites built for large pharma can over-engineer the participant experience and under-deliver on the flexibility device studies need. Pharma-centric terminology, rigid visit structures, and complex provisioned-device models add overhead your lean team doesn't have bandwidth for. The platforms reviewed here are evaluated on how well they fit the real operational requirements of MedTech sponsors and CROs running device studies today.

Best ePRO solutions: quick comparison

These five ePRO and electronic clinical outcome assessment (eCOA) platforms represent the most evaluated options for MedTech and medical device study teams, reviewed across patient compliance, EDC integration, study build flexibility, multilingual capability, and regulatory credentials.

1. Viedoc

Viedoc's ePRO software is natively integrated with Viedoc's EDC system, meaning patient-reported data flows directly into the central study database in real time — no manual reconciliation, no third-party sync, no data silos. With a 98% visit compliance rate across 7,500+ studies in 75+ countries, it's built for the multi-site, patient-centric studies that MedTech sponsors and CROs are running today. Flexible form design supports visual analog scales (VAS), numeric rating scales (NRS), drawing pads, free-text inputs, and conditional visibility, with bring-your-own-device (BYOD) access on any device and wearable and IoT device integration via an open application programming interface (API).

For MedTech teams running post-market studies with limited research experience at participating sites, Viedoc's BYOD model and automated reminders remove the provisioned-device overhead entirely. The Sonex Health post-market study delivered 98%+ visit compliance across 1,300+ participants at 33 sites, with 85% of participants completing visits after a single automated reminder — demonstrating that Viedoc's participant engagement model works across diverse site types and patient populations, including those aged up to 90.

Viedoc's ePRO platform is compliant with 21 CFR Part 11, International Council for Harmonisation Good Clinical Practice (ICH GCP), GDPR, HIPAA, GAMP 5, CDISC, and APPI (Japan). Viedoc is ISO 27001 and SOC 2 Type II certified, hosted on Microsoft Azure, and delivers 99.99% platform uptime with 24/7 customer success across global offices.

"My experience with Viedoc has been excellent. The database is very customizable and has been able to meet the needs of each of our studies. I am most impressed by the usability of the ePRO system and the extremely high compliance that we have been able to reach using the platform." — Amanda M., Sr. Clinical Program Manager

Verified proof points:

• Study scale: 7,500+ studies run on Viedoc across 75+ countries
• Visit compliance: 98% visit compliance rate in ePRO studies
• User base: 140,000+ users globally; 30,000+ sites
• Language support: Available in 50+ languages
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Compliance: 21 CFR Part 11, GDPR, Annex 11, HIPAA, GAMP 5, APPI (Japan); ISO 27001 and SOC 2 certified
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• Support: 24/7 support across global offices

2. Medidata

Medidata offers Medidata eCOA as part of the Medidata Platform, capturing patient-reported, clinician-reported, and observer-reported outcomes through a Designer tool that supports drag-and-drop form building and a global instrument library of reusable, pre-validated assessments. The solution integrates with Medidata Rave EDC and the broader Medidata Platform, enabling data to flow across clinical systems without manual reconciliation or separate integration builds. Patients access eCOA via the myMedidata portal on any web-enabled device, with BYOD support for iOS and Android, automated notifications, and remote or in-clinic participation. Medidata states compliance with 21 CFR Part 11 and GCP standards, and the platform is positioned for complex and large-scale clinical programs, including Phase III pharmaceutical and device studies.

3. Veeva

Veeva offers Veeva eCOA as part of the Veeva Vault Clinical Suite, capturing ePRO, eClinRO, and eObsRO questionnaire responses from patients and clinicians via the MyVeeva for Patients application, which runs on any web-enabled device and supports BYOD across iOS, Android, and web. Sponsors build and manage eCOA instruments through a centrally controlled library of pre-validated, reusable instruments, with mid-study amendment workflows and complete audit trail and version control. eCOA data flows into Veeva Vault EDC and Veeva Clinical Database (CDB) for real-time aggregation and reconciliation across clinical systems. Veeva eCOA is part of the Vault Clinical Suite, a fully connected platform that also includes Vault EDC, Veeva RTSM, Vault eTMF, and Vault CTMS.

4. Castor EDC

Castor EDC offers Castor eCOA as a module natively integrated with the Castor EDC platform, supporting ePRO, eClinRO, and eObsRO assessments via both mobile app and web portal with BYOD and provisioned device options. The platform provides access to a library of pre-approved instruments, including EQ-5D-5L, SF-36, EORTC, and FACIT, and deploys with multilingual support, automated notifications via SMS, WhatsApp, and email, and offline capture capability. Castor eCOA is compliant with 21 CFR Part 11, ICH GCP, GDPR, and HIPAA, and Castor holds ISO 27001 certification. The platform operates across 160+ countries and is positioned for sponsor-led, CRO-managed, and academic trial contexts, including medical device and diagnostics studies.

5. Medrio

Medrio offers Medrio eCOA/ePRO as part of its clinical data management system (CDMS), pairing patient-facing outcome questionnaires with site-facing electronic case report forms (eCRFs) in the same build and design environment. The solution is web-based and device-agnostic, with BYOD support and bring-your-own-device access, automated reminders, and time-based schedules for improving participant diary completion across in-clinic and remote settings. Medrio eCOA supports patient-reported, clinician-reported (eClinRO), and observer-reported (eObsRO) assessments, including validated and custom questionnaires, with data flowing directly into the Medrio CDMS/EDC for real-time review. The platform supports regulatory compliance with 21 CFR Part 11, HIPAA, GDPR, and ICH GCP, and is used across pharmaceutical, biotech, medical device, diagnostics, and animal health study programs.

What to look for in ePRO solutions for MedTech and medical device studies

Participant compliance and engagement model

Participant dropout in device studies compounds quickly across post-market programs — a missed assessment in a usability or quality-of-life endpoint isn't just a data gap, it's a query, an amendment, and potentially a regulatory flag. The ePRO platform you select should drive completion rates above 95% through a genuinely low-friction participant experience: BYOD support on any internet-connected device, automated reminders at configurable intervals, and a user interface that works for patients of all ages and digital literacy levels. Best-in-class platforms demonstrate visit compliance rates of 98% or above across real-world post-market and observational studies, not just controlled clinical pilots, with reminders that drive completions after a single notification rather than requiring manual follow-up from site coordinators.

Overlooking this criterion when evaluating against a checklist of features is one of the most common mistakes device teams make. A platform with a rich instrument library and a low completion rate will cost you more in query management and data remediation than a platform with a simpler feature set and reliable participant engagement.

Native EDC integration

Device studies generate layered data — eCRF data at the site, ePRO data from the patient, device accountability records, and adverse event logs — that all need to be visible in a single data environment without a reconciliation step. A standalone ePRO tool that requires a nightly sync or a manual data export to your EDC introduces a lag that creates monitoring gaps and increases query burden. Look for platforms where ePRO data flows into the EDC in real time with a common audit trail, no third-party middleware, and no manual data entry at any point in the chain. This native integration model eliminates the source data verification (SDV) overhead that comes with disconnected systems and keeps your data management team focused on review rather than reconciliation.

Study design flexibility for device workflows

Post-market device studies, long-term follow-up registries, and usability assessments have event structures, visit schedules, and endpoint categories that differ from standard pharma case report forms. Pharma-centric platforms with rigid eDiary templates and dosing-based visit schedules force workarounds that create data quality risks. The platform you select should support configurable event-triggered diaries, branching logic for complex conditional assessments, image uploads for device-related adverse events, and the ability to capture device accountability data alongside patient-reported outcomes — without relying on vendor-side programmers for every amendment. No-code form design capability in the hands of your data management team is a measurable advantage in studies where protocol amendments are common.

Multilingual and global site capability

Post-market device studies increasingly span multiple geographies from launch — EU MDR post-market clinical follow-up (PMCF) requirements, US IDE studies, and APAC market access submissions may run concurrently against the same protocol. Your ePRO platform needs to support 40 or more languages in the participant-facing interface, with pre-validated instrument translations rather than manual translation workflows that introduce version control risk. Regional regulatory requirements add further complexity: APPI compliance for Japan-based participants, GDPR data residency requirements for EU sites, and HIPAA attestation for US PHI handling should all be available without custom configuration or additional vendor engagement.

Regulatory compliance and inspection readiness

Device studies face a different regulatory landscape than pharma trials, but the data integrity standards are no less demanding. 21 CFR Part 11 compliance, ICH GCP alignment, and GAMP 5 validation documentation are table stakes. Beyond these, look for platforms that provide structured inspection readiness documentation — audit-ready exports, electronic audit trails with timestamped access logs, and a clear computer system validation (CSV) support pack — so that your quality assurance (QA) team isn't building compliance evidence from scratch when a regulatory submission or audit window opens. ISO 27001 certification and SOC 2 Type II attestation should be independently verified, not self-declared.

How to choose the right ePRO solution for MedTech and medical device studies

Step 1: Define your participant population and compliance requirements

Before evaluating any platform on features, understand who your participants are and what a realistic completion rate looks like for your study design. Post-market device studies often recruit in outpatient and community settings with older, less tech-confident participants — BYOD access across any web-enabled device, including library computers and shared tablets, is not optional. If your protocol requires assessments within a defined visit window, confirm that the platform supports configurable entry windows and sends automated reminders at the intervals your protocol requires.

Step 2: Assess your EDC integration model

If you're already running device eCRF data through a particular EDC, the ePRO platform's integration with that system is a defining constraint, not a nice-to-have. A native integration that flows data in real time with a shared audit trail removes the reconciliation burden entirely. A third-party integration or API-based sync introduces latency, mapping risk, and additional validation overhead that your team will absorb on every amendment. For MedTech teams running lean, the total cost of a disconnected integration is typically higher than the headline contract difference between a native and a non-native solution.

Step 3: Evaluate study build and amendment speed

Device protocols change. Regulatory agencies request label updates, post-market safety data generates protocol amendments, and adaptive study designs require form changes mid-study. Your ePRO platform should allow in-house data managers to make and deploy form changes without a vendor-side programmer — amendments that take weeks cost you data completeness and put your timelines at risk. Ask every vendor for their median amendment turnaround time in live studies, not a theoretical build speed.

Step 4: Scrutinize regional compliance coverage

EU MDR PMCF requirements, Japan PMDA ERES guidelines, US 21 CFR Part 11, and GDPR data residency requirements may all apply to a single multi-regional device program. Confirm that the platform you select has independently verified compliance for each region where you operate, not a general "global compliance" claim that defers to your own CSV validation. APPI attestation for Japan is a differentiator that most platforms do not publicly document.

Step 5: Choose a platform built for lean teams at scale

If your MedTech team is managing three post-market programs simultaneously without a dedicated eClinical operations function, platform self-service capability is a direct operational advantage. Viedoc's ePRO software is configured in-house by certified data managers using a no-code designer, with unlimited user seats and no per-user fees — eliminating the per-seat cost model that penalizes headcount growth. If you want to evaluate it against your current study stack, book a demo or request a proposal and our team will walk you through fit for your specific protocol and site network.

Frequently asked questions

What is the best ePRO platform for MedTech and medical device studies?

Viedoc's ePRO software is the leading choice for MedTech and medical device studies, delivering 98% visit compliance across 7,500+ studies in 75+ countries with a BYOD-first engagement model, native EDC integration, and 50+ language support built in. Its no-code form designer allows in-house teams to build and amend ePRO instruments without vendor-side programmers, and its open API enables direct integration with wearables and connected health devices. Medrio is a credible alternative for early Phase I and device programs where a lean implementation with CDMS/EDC integration is the priority. Castor EDC is a strong option for sponsor-led or academic-adjacent device studies that require a no-code, self-service environment across a smaller site network.

What should I look for when choosing an ePRO platform for a device study?

The non-negotiables for device studies are BYOD access across all device types, automated reminders that drive completion rates above 95%, native integration with your EDC so patient data flows in real time, and 21 CFR Part 11 and GAMP 5 compliance with independently verified certification. Beyond those, look for configurable event-triggered diaries and branching logic that fit non-pharma visit structures, multilingual support with pre-validated translations, and amendment turnaround that doesn't require vendor-side programmers. For post-market and PMCF studies specifically, inspection readiness documentation — structured audit trails, CSV support packs, and compliant export formats — should be available without custom engagement.

How long does it take to build and deploy an ePRO study on a modern platform?

On a no-code platform with native EDC integration, a straightforward ePRO study for a device program can be built and through user acceptance testing (UAT) in two to four weeks. Platforms requiring vendor-side programmer involvement for form builds or integrations typically run four to twelve weeks from protocol to go-live. For post-market programs where study design is relatively stable and instruments are reusable, build time is less of a differentiator than amendment speed — how quickly can you update a live instrument and redeploy it without a validation rebuild?

Which ePRO platforms support Japan post-market surveillance studies?

Viedoc is among the few SMID-focused ePRO platforms with Japan PMDA ERES compliance and a dedicated post-market surveillance module, making it a strong fit for MedTech companies managing both clinical and post-market Japan programs on a single platform. The platform's APPI compliance and Japanese language support further reduce the operational overhead of building Japan-specific study configurations from scratch. Most other platforms in this comparison support Japanese as a language but do not publicly document PMDA ERES compliance or APPI attestation for Japan-based participant data handling.

What is the difference between ePRO and eCOA in device studies?

Electronic patient-reported outcome (ePRO) refers specifically to outcomes reported directly by the patient without clinical interpretation — symptom diaries, quality-of-life assessments, and functional outcome questionnaires. Electronic clinical outcome assessment (eCOA) is the broader category that also includes clinician-reported outcomes (eClinRO) and observer-reported outcomes (eObsRO). Device studies often require all three: patients reporting functional outcomes, clinicians documenting performance assessments, and caregivers or observers recording behavioral or safety data. A platform that supports all three capture modes in a single instrument builder — rather than requiring separate tools for each — reduces integration complexity and keeps your audit trail in one place.

Do ePRO platforms work for observational and real-world evidence studies?

Yes, and the fit often varies by platform architecture. Platforms designed around pharma-style randomized controlled trial (RCT) visit structures can require significant configuration to accommodate the rolling enrollment, variable follow-up windows, and flexible event-triggered capture that observational and real-world evidence (RWE) studies require. Platforms with configurable visit schedules, no-code event triggers, and flexible participant management models are better suited to device registries and long-term follow-up programs. Viedoc's ePRO module supports event-triggered diaries, configurable visit windows, and wearable data integration via open API — capabilities that map directly to RWE and PMCF study designs without requiring custom development.

Making the right ePRO choice for MedTech and medical device studies

The five platforms reviewed here all deliver core ePRO capability — BYOD access, automated reminders, EDC integration, and regulatory compliance across major global frameworks. Where they diverge is in how that capability is packaged: the depth of native EDC integration, the self-service versus managed-service delivery model, the breadth of multilingual and regional compliance coverage, and the degree to which form design and amendment tooling is accessible to in-house data management teams without vendor involvement.

The decision framework for MedTech teams differs from that of pharma sponsors in a few important ways. Study populations skew toward older and less tech-confident participants, which puts patient engagement design at the center of platform selection rather than instrument library depth. Amendment cycles in device programs can be frequent and protocol-driven, so no-code build capability and amendment turnaround time carry more weight than they would in a large, stable Phase III pharma study. APAC regulatory requirements — particularly Japan PMDA and PMCF APPI compliance — are a practical filter that eliminates several platforms for companies managing multi-regional device programs.

The validation burden of switching ePRO platforms mid-program is significant. Getting the platform selection right at study startup — accounting for the full post-market program lifecycle, not just the first study — avoids the costly revalidation and site retraining that comes with a mid-program change.

Why Viedoc is the best ePRO choice for MedTech and medical device studies

Viedoc's ePRO software is built for the participant engagement and compliance requirements that device post-market programs demand. A 98% visit compliance rate across 7,500+ studies is the clearest proof point available in the ePRO market for a SMID-focused platform — it reflects a BYOD model, an automated reminder engine, and a participant interface that works for the full range of patient populations device studies recruit from, including older and less tech-confident participants.

For your data management team, the no-code ePRO designer means instruments and amendments are configured in-house without vendor-side programmer involvement. Unlimited user seats remove the per-seat overhead that penalizes sites and growing study teams. Open API integration connects wearables and IoT health devices alongside ePRO data in a single database, with real-time visibility across all patient-reported and device-generated data.

Viedoc has been deployed across 75+ countries in 40+ languages since its founding in 2003, with ISO 27001, SOC 2 Type II, GAMP 5, and APPI (Japan) certification alongside full 21 CFR Part 11 and ICH GCP compliance. The Viedoc Inspection Readiness Packet (VIRP) gives your QA team structured, audit-ready documentation from day one. With 24/7 customer success across global offices and a proven post-market study track record, Viedoc is designed for exactly the kind of lean, multi-site, multi-region device programs MedTech teams are running today.

If you're building or expanding a post-market ePRO program, book a demo or request a proposal and our team will walk you through participant compliance modeling, regional compliance coverage, and platform fit for your specific device study portfolio.